Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants

Primary Objective:

• To describe the safety profile of the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines in healthy adults, adolescents, toddlers and infants, when administered alone (Stages 1-4) or concomitantly with MenQuadfiTM (MenACYW conjugate vaccine) (for Stages 2-4 only), and with age-appropriated routine pediatric vaccines (for Stages 3-4 only)

  1. To describe the safety profile of the SP MenB vaccine formulations, Bexsero Vaccine and Trumenba Vaccine in healthy adults, and adolescents;
  2. To describe the safety profile of the SP MenB vaccine formulations and Bexsero Vaccine in toddlers and infants;

  3. To describe the safety profile of the SP MenB vaccine formulations,

     • when administered alone
     • when administered with MenQuadfiTM (MenACYW conjugate vaccine)
     • when administered with routine infant immunizations
• To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines after the last dose of primary vaccination in healthy adults, adolescents, toddlers and infants, when administered alone, or concomitantly with MenQuadfi Vaccine or other routine vaccines, as measured by the serum bactericidal assay using human complement (hSBA) in the primary panel of MenB strains by Stage, by age group and by vaccine schedule

Secondary Objective:

• To describe the immune response to the SP MenB vaccine formulations and the 2 licensed MenB comparator vaccines at each timepoint in healthy adults, adolescents, toddlers and infants, when administered alone or concomitantly with MenQuadfi Vaccine or other routine vaccines as measured by hSBA in the primary panel of MenB strains by Stage by age group and by vaccine schedule
• To describe the immune response (breadth of coverage) in the secondary panel of MenB strains in participants (adults and adolescents) in Stage 1 and 2 after the last dose of the primary series in each group
• To describe the persistence of immune response following primary series at D366, and immune response 1 month after a booster dose of the SP MenB vaccine given 1-year post-dose 1 (at D366) in a subset of adults and adolescents in Stage 2 who received SP MenB vaccine formulations, Bexsero Vaccine or Trumenba Vaccine as measured by hSBA in the primary panel of MenB strains by age group
• To describe the immune response against meningococcal serogroups A, C, W and Y measured with hSBA in participants from each agegroup receiving MenQuadfi Vaccine

Study Overview

• Status: Active, not recruiting
• Conditions: Meningococcal Immunisation
• Intervention / Treatment: Drug: Meningococcal Group B Vaccine MenB; Drug: Placebo; Drug: Multicomponent Meningococcal B Vaccine; Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed); Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine

Detailed Description

Study duration per participant will be approximately: 7 months for Stage 1 participants, 12 to 18.5 months for Stage 2 participants, 12 months for Stage 3 participants and 18 months for Stage 4 participants

In each vaccine group at each age group (Stage 1, 3 and 4 only), the first 5 participants enrolled (sentinels) will be assessed via early safety data review (ESDR) as a cohort for the evaluation of biological safety and overall safety profile for D01-D08 post dose 1. The safety data collected will be reviewed before proceeding with recruitment of remaining participants in each study group. Enrollment of remaining participants randomized to each group will be based on the outcome of the safety assessments of the sentinels: only a positive review outcome will allow the enrollment of the sentinel cohort of the respective lower age group.

• Study Type: Interventional
• Enrollment (Actual): 576
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Trial Transparency email recommended (Toll free number for US & Canada); Phone Number: option 6 800-633-1610; Email: Contact-US@sanofi.com

Study Locations

• Puerto Rico
  • Ponce, Puerto Rico, 00716
    • Investigational Site Number :6300003
  • San Juan, Puerto Rico, 00918
    • Investigational Site Number :6300001
• United States
  • Alabama
    • Guntersville, Alabama, United States, 35976
      • Lakeview Clinical Research-Site Number:8400029
  • California
    • Canoga Park, California, United States, 91301
      • Hope Clinical Research, Inc.-Site Number:8400001
    • Cypress, California, United States, 90630
      • WCCT Global, Inc.-Site Number:8400015
    • San Diego, California, United States, 92123-1881
      • California Research Foundation-Site Number:8400005
  • Florida
    • Gainesville, Florida, United States, 32607
      • SIMEDHealth, LLC-Site Number:8400045
    • Hallandale Beach, Florida, United States, 33009
      • MD Clinical-Site Number:8400027
    • Tampa, Florida, United States, 33609
      • Moore Clinical Research Inc-Site Number:8400030
    • Tampa, Florida, United States, 33613
      • PAS Research, LLC-Site Number:8400032
  • Idaho
    • Meridian, Idaho, United States, 83642
      • Advanced Clinical Research - Magic View-Site Number:8400024
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Brengle Family Medicine-Site Number:8400044
  • Kansas
    • El Dorado, Kansas, United States, 67042
      • AMR El Dorado-Site Number:8400018
    • Wichita, Kansas, United States, 67205
      • Alliance for Multispecialty Research LLC-Site Number:8400013
    • Wichita, Kansas, United States, 67207
      • AMR Wichita East-Site Number:8400012
  • Kentucky
    • Bardstown, Kentucky, United States, 40004
      • Kentucky Pediatric Research Inc-Site Number:8400009
    • Lexington, Kentucky, United States, 40509
      • AMR Lexington-Site Number:8400002
    • Lexington, Kentucky, United States, 40517
      • Michael W. Simon, MD, PSC-Site Number:8400026
  • New York
    • New York, New York, United States, 10456
      • Prime Global Research, Inc.-Site Number:8400043
  • South Carolina
    • Greenville, South Carolina, United States, 29607
      • The Research Center of the Upstate-Site Number:8400008
  • Tennessee
    • Tullahoma, Tennessee, United States, 37388
      • Pediatric Clinical Trials Tullahoma-Site Number:8400020
  • Utah
    • Bountiful, Utah, United States, 84010
      • Progressive Clinical Research-Site Number:8400028

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 month to 50 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion criteria :

-For US: Aged 10 to 25 years on the day of inclusion ("10-25 years" means from the day of the 10th birthday to the day before the 26th birthday) For EU: Aged 42 to 89 days or 12 to 18 months or 10 to 50 years on the day of inclusion ("42 to 89 days" means from 42 days after birth to the 89th day after birth; "12-18 months" means from the12th month after birth to the day before the 19th month after birth; "10-50 years" means from the day of the 10th birthday to the day before the 51st birthday Participants or participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures Covered by health insurance (applicable depending on local regulations) Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgement of the Investigator

For adults: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR
• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) the day of any dose of study intervention

For adolescents: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

• Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be pre-menarche OR
• Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 4 weeks after the last study intervention administration A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) the day of any dose of study intervention -For infants: Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period of 27 through 36 weeks and medically stable as assessed by the investigator, based on the following definition: "Medically stable" refers to the condition of premature infants who do not require significant medical support or ongoing management for debilitating disease and who have demonstrated a clinical course of sustained recovery by the time they receive the first dose of study intervention - - -

Exclusion criteria:

-Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months or since birth for infants and toddlers; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months or since birth for infants and toddlers) History of any Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically At high risk for meningococcal infection during the trial (specifically, but not limited to, participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease) Individuals with active tuberculosis Known systemic hypersensitivity to latex or to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances For adults and adolescents: Self-report of thrombocytopenia, contraindicating intra-muscular (IM) vaccination * For infants and toddlers: Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/legally acceptable representative contraindicating intramuscular vaccination Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination For infants and toddlers: History of intussusception Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine 4 weeks before to 4 weeks after each trial vaccination or study visit with collection of blood for immunogenicity assessments, except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines Previous vaccination against meningococcal B disease with either the study vaccines or another licensed or investigational vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroup B) For infants and toddlers: Previous vaccination against meningococcal disease with either the study vaccines or any other licensed or investigational vaccine containing serogroups A, C, W, Y; or meningococcal serogroup B Receipt of immune globulins, blood or blood-derived products in the past 3 months or since birth for infants and toddlers Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first immunogenicity blood draw For infants: Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis A, measles, mumps, rubella, varicella; and Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection or disease, and receipt of more than 1 previous dose of hepatitis B vaccine Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion Moderate or severe acute illness/infection (according to the investigator's judgment), febrile illness (temperature ≥ 38.0°C or ≥ 100.4°F). A prospective participant should not be enrolled in the study until the condition has resolved or the febrile event has subsided History of Guillain-Barré syndrome History of any neurologic disorders, including any seizures and progressive neurologic disorders Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily For adults and adolescents: Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the investigator or employee with direct involvement in the proposed study For infants and toddlers: Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study For adults and adolescents: Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stage 1: MenB vaccine formulation(s); Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181	Drug: Meningococcal Group B Vaccine MenB; Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: MenB; Drug: Placebo; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Active Comparator: Stage 1: vaccine comparator(s); Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181	Drug: Placebo; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Drug: Multicomponent Meningococcal B Vaccine; Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular; Other Names: Trumenba®; Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed); Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: Bexsero®
Experimental: Stage 2: MenB vaccine formulation(s); Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366	Drug: Meningococcal Group B Vaccine MenB; Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: MenB; Drug: Placebo; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Other Names: MenQuadfi™
Active Comparator: Stage 2: vaccine comparator(s); Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366	Drug: Placebo; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Drug: Multicomponent Meningococcal B Vaccine; Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular; Other Names: Trumenba®; Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed); Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: Bexsero®
Experimental: Stage 3: Men B vaccine formulation(s); Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61	Drug: Meningococcal Group B Vaccine MenB; Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: MenB; Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Other Names: MenQuadfi™
Active Comparator: Stage 3: MenQuadfi vaccine and vaccine comparator; MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61	Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed); Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: Bexsero®; Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Other Names: MenQuadfi™
Experimental: Stage 4: MenB vaccine formulation(s); Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa	Drug: Meningococcal Group B Vaccine MenB; Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: MenB; Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Other Names: MenQuadfi™
Active Comparator: Stage 4: MenQuadfi vaccine and vaccine comparator; MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa	Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed); Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular; Other Names: Bexsero®; Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular; Other Names: MenQuadfi™

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with immediate adverse events (AEs)	Unsolicited systemic AEs that occur within 30 minutes after vaccination	Within 30 minutes after vaccination
Number of participants with solicited injection site reactions or systemic reactions	Adverse reactions pre-listed in the protocol and case report form (CRF) Injection site reactions: pain, erythema and swelling (or tenderness, erythema and swelling for infants and toddlers) Systemic reactions: fever, headache, malaise, myalgia (or fever, vomiting, crying abnormal, drowsiness, appetite lost, irritability for infants and toddlers)	Within 7 days after vaccination
Number of participants with unsolicited AEs	AEs that do not fulfill the conditions of solicited reactions	Within 30 days after vaccination
Number of participants with serious adverse events (SAEs)	SAEs reported throughout the study, including adverse events of special interest (AESI)s	Up to 6 months after last vaccination
Number of participants with medically attended adverse events (MAAE)s	AEs with a new onset or a worsening of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a physician's office or Emergency Department	Up to 6 months after last vaccination
Number of participants with out-of-range biological test results	Out-of-range biological test results occurring in the sentinel cohorts of each age group	From baseline (pre-vaccination) up to Day 07 (post-vaccination)
Antibody titers in the primary panel of MenB strains before primary vaccination	Antibody titers measured by serum bactericidal assay using human complement (hSBA)	Day 01 (pre-vaccination)
Antibody titers in the primary panel of MenB strains after primary vaccination	Antibody titers measured by hSBA	Day 30 (post-vaccination)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antibody titers in the primary panel of MenB strains after each vaccination	Antibody titers measured by hSBA	Day 01, Day 31, Day 61, Day 91, Day 181, Day 211, Day 366 and Day 396
Antibody titers in the secondary panel of MenB strains (stage 1 and 2 only)	Antibody titers measured by hSBA	Day 01 (pre-vaccination) and Day 30 (post-vaccination)
Antibody titers in the primary panel of MenB strains (stage 2 only)	Antibody titers measured by hSBA	Day 366 (pre-vaccination) and Day 396 (post-vaccination)
Antibody titers against each of Men A, C, W, and Y strains	Antibody titers measured by hSBA in participants receiving MenQuadfi vaccine	Day 01 (pre-vaccination) and Day 30 (post-vaccination)

Collaborators and Investigators

• Sponsor: Sanofi Pasteur, a Sanofi Company
• Investigators: Study Director: Clinical Sciences & Operations, Sanofi

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2021
• Primary Completion (Estimated): May 5, 2026
• Study Completion (Estimated): May 5, 2026

Study Registration Dates

• First Submitted: March 25, 2021
• First Submitted That Met QC Criteria: March 30, 2021
• First Posted (Actual): April 1, 2021

Study Record Updates

• Last Update Posted (Actual): September 29, 2023
• Last Update Submitted That Met QC Criteria: September 27, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: VAN00002; U1111-1244-0377 (Other Identifier: UTN)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes